User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

6542

Interactions with Platform & by Email *

INTERACTIONS

1047

Unique # Participated *

PARTICIPANTS

196

Responses Validated *

VALIDATIONS

42

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Psoriasis – A Chronic, Widespread Autoimmune Disease.....II-1
Table 1: World Psoriasis Prevalence (in Million) in Select Countries: 2007-2015 (includes corresponding Graph/Chart).....II-1
1$350
   Psoriasis Poses Risk for Cardiovascular Diseases.....II-2
Quick Facts About Psoriasis Disease.....II-2
Quick Facts About Psoriasis Treatment.....II-2
1$100
   Global Market Outlook.....II-3
Psoriasis Drugs Overview.....II-3
1$100
   Major Marketed Drugs for Psoriasis Treatment as of 2009.....II-4
Topical Drugs Overview.....II-4
1$100
   Table 2: World Psoriasis Drugs Market - Value Sales of Select Leading Topical Products in US$ Million for 2008 (includes corresponding Graph/Chart).....II-5
Foams and Liquid Formulations Gaining Momentum.....II-5
JAK3 Inhibitors Spell Promising Future for Topical Drugs.....II-5
Systemic Drugs Overview.....II-5
1$350
   Table 3: World Psoriasis Drugs Market - Value Sales of Select Leading Conventional Systemic Products in US$ Million for 2007 (includes corresponding Graph/Chart).....II-6
Enbrel – The Market Leader.....II-6
1$350
   Market Welcomes New Products, Even As Established Biologic Makes Exit.....II-7
Conventional Topical Therapies to Remain Mainstay Treatment.....II-7
1$100
   Biologics to Witness Robust Growth, Driven by New Product Introductions.....II-8
Interleukin and TNF-Alpha Inhibitors to Drive Biologics Growth.....II-8
TNF-Alpha Blockers – The Market Leaders.....II-8
1$100
   Table 4: World Psoriasis Drugs Market - Value Sales of Select Leading Biologic Systemic Products in US$ Million for 2008(includes corresponding Graph/Chart).....II-9
Interleukin Inhibitors – The Next Big Biologic Class.....II-9
1$350
   Non-Prescriptions and Generics Threaten Market Growth.....II-10
Oral Pipeline Therapies To Take On Biologics.....II-10
Home Ultraviolet B Therapy to Find Favor with Psoriasis Patients.....II-10
1$100
   Paradigm of Psoriasis Treatment.....II-11
Voclosporin to Edge Out Competitive Products.....II-11
Apremilast to OUTdo Existing Anti-TNF Products.....II-11
2$125
   The Research Progress in Psoriasis Treatment.....II-13
Safety Plays Critical Role in Psoriasis Therapy.....II-13
Major Drug Candidates in Pipeline.....II-13
1$100
   Existing and Future Research & Development Approach.....II-14
Table 5: Psoriasis Drugs Pipeline (2009) - Number of Pipeline Candidates and Clinical Trials (includes corresponding Graph/Chart).....II-14
1$350
   Select Psoriasis Pipeline Candidates for Topical Treatment as of 2009.....II-151$100
   Select Psoriasis Pipeline Candidates for Oral Treatment as of 2009.....II-16
Select Psoriasis Pipeline Candidates for Injectable Treatment as of 2009.....II-16
1$100
   Other Major Psoriasis Pipeline Candidates in Phase II Clinical Trials as of
  2009.....II-17
NIAID Researchers Identify Potential New Drug Target.....II-17
1$100
   What is Psoriasis?.....II-18
The History of Psoriasis.....II-18
The History of Psoriasis Treatment.....II-18
1$100
   The Risk Factors of Psoriasis.....II-19
The Cause(s) of Psoriasis.....II-19
The Aggravating Factors.....II-19
1$100
   The Diagnosis of Psoriasis.....II-20
The Severity of Psoriasis.....II-20
1$100
   The Types of Psoriasis.....II-21
Plaque Psoriasis.....II-21
Scalp Psoriasis.....II-21
Nail Psoriasis.....II-21
Inverse Psoriasis.....II-21
1$100
   Guttate Psoriasis.....II-22
Pustular Psoriasis.....II-22
Erythrodermic Psoriasis.....II-22
1$100
   Psoriatic Arthritis.....II-23
Others.....II-23
The Treatment of Psoriasis.....II-23
The Three-Step Approach to Treatment.....II-23
Treatment by Disease Severity.....II-23
1$100
   Mild Stage Psoriasis Treatment.....II-24
Moderate Stage Psoriasis Treatment.....II-24
Severe Stage Psoriasis Treatment.....II-24
Treatment by Natural Healing.....II-24
1$100
   Other Treatment.....II-251$100
   Table 6: Therapeutic Modalities for Psoriasis Treatment in Percentage by Disease Stage (includes corresponding Graph/Chart).....II-261$350
   Topical Treatment.....II-27
List of Topical Therapies Available for the Treatment of Mild-to-Moderate
  Psoriasis.....II-27
Select Topical Drugs.....II-27
Clobex (Clobetasol propionate).....II-27
1$100
   Dovonex (calcipotriene).....II-28
Olux-E (Clobetasol propionate).....II-28
Taclonex/ Dovobet/ Daivobet (calcipotriene/ betamethasone).....II-28
1$100
   Tazorac (Tazarotene).....II-29
Vectical (calcitriol).....II-29
Systemic Treatment.....II-29
1$100
   Conventional Systemic Therapies.....II-30
Select Conventional Systemic Drugs.....II-30
Methotrexate.....II-30
Soriatane (acitretin).....II-30
Neoral (cyclosporine).....II-30
Tegison (etrentinate).....II-30
NSAIDs.....II-30
1$100
   Biologic Systemic Therapies.....II-31
List of Approved Biologic Systemic Therapies for Psoriasis.....II-31
1$100
   Select Biologic Drugs.....II-32
Amevive (alefacept).....II-32
Enbrel (etanercept).....II-32
Humira (adalimumab).....II-32
1$100
   Remicade (infliximab).....II-33
Raptiva (efalizumab).....II-33
Stelara (ustekinumab).....II-33
1$100
   Phototherapy.....II-34
UVB Phototherapy.....II-34
PUVA Phototherapy.....II-34
1$100
   Alternative Treatment.....II-35
Climatotherapy.....II-35
1$100
   Isotechnika’s Voclosporin Shows Favorable Results in Phase III Clinical Trial.....II-36
Provectus Commences New PH-10 Clinical Trials for Psoriasis.....II-36
Micromet Initiates First Clinical Study for GM-CSF Human Antibody MT203.....II-36
Welichem Initiates GLP Toxicology Studies for WBI-1001.....II-36
Anacor Announces Favorable Phase II Trial Results of AN2728.....II-36
1$100
   Synvista Initiates Phase II Clinical Trial of Topical SYI-2074.....II-37
Avontec Announces Positive Results from Phase IIa Clinical Trial of AVT-02 UE.....II-37
Revotar Announces Favorable Phase I Trial Results of Bimosiamose 5% Cream.....II-37
Manhattan Completes Enrollment in Phase IIa Clinical Trial of Topical PTH
  (1-34).....II-37
1$100
   Dermipsor Announces Positive Results from Phase IIb Clinical Trial of DPS-101.....II-38
BioCryst Completes Phase IIa Study, Announces Promising Results of BCX-4208.....II-38
Arana Therapeutics Completes Patient Recruitment in Phase II Trial of ART621.....II-38
Novartis Exploratory Development Study Shows Positive Results for AEB071.....II-38
2$125
   Eisai Obtains Japanese Approval for HUMIRA® in Psoriasis Treatment.....II-40
Janssen-Cilag Launches Stelara® for Plaque Psoriasis.....II-40
PsoriasisDX Launches Genetic Test for Psoriatic Arthritis.....II-40
1$100
   Elorac Launches Zithranol-RR for Plaque Psoriasis.....II-41
Quinnova Introduces New Treatment for Hyperkeratotic Conditions.....II-41
Xderma Launches New Ointment for Psoriasis.....II-41
1$100
   Promius Pharma Introduces Scytera Foam 2% for Chronic Psoriasis.....II-42
NeoStrata Launches PSORENT.....II-42
LEO Pharma to Launch Xamiol®.....II-42
Glenmark Introduces Dermatology Products.....II-42
1$100
   The Kuwait Health Ministry Approves Alalorid for Psoriasis Treatment.....II-43
CHMP’s Positive Recommendation for Enbrel as Psoriasis Treatment in Children.....II-43
1$100
   Cephalon Acquires Arana Therapeutics.....II-44
GlaxoSmithKline to Acquire Stiefel Laboratories.....II-44
PhotoMedex Acquires Photo Therapeutics.....II-44
PPD Acquires Magen BioSciences.....II-44
1$100
   Bristol-Myers Squibb Acquires Medarex.....II-45
Valeant Pharmaceuticals Acquires Dow Pharmaceutical Sciences.....II-45
Advitech to Acquire Botaneco Specialty Ingredients.....II-45
1$100
   Merck Merges with Schering-Plough.....II-46
Pfzer Acquires Wyeth.....II-46
Paladin Labs and Isotechnika Pharma Enter into Partnership.....II-46
1$100
   Centocor Ortho Biotech Obtains FDA Approval for Golimumab.....II-47
Centocor Ortho Biotech Obtains FDA Approval for Stelara™.....II-47
Galderma Receives Approval from FDA for Vectical.....II-47
LEO Pharma Reacquires Product Licensing Rights from Warner Chilcott.....II-47
1$100
   Genentech Withdraws Raptiva from US Market.....II-48
Prime Pharmaceutical Grants License of Relieva® to Mac Pharma.....II-48
1$100
   Dynavax Receives Grant to Support TLR Inhibitors Development from NIAID.....II-49
Valeant Pharmaceuticals Takes Over DermaTech.....II-49
Bayer Takes Over Direvo Biotech.....II-49
Stiefel Laboratories Acquires Barrier Therapeutics.....II-49
1$100
   Biotie Therapies Enters in Agreement to Acquire elbion.....II-50
Galderma Acquires Collagenex.....II-50
1$100
   Abbott Obtains FDA Approval for HUMIRA® in Psoriasis Treatment.....II-51
LEO Pharma and Warner Chilcott Obtain FDA Approval for Taclonex Scalp®.....II-51
Cytos Joins Hands with Pfizer to Develop Vaccines.....II-51
Karo Bio and Zylus Cadila Enter into Collaboration.....II-51
1$100
   Dermipsor Collaborates with Department of Veterans Affairs and VA Boston Research
  Institute.....II-52
GlaxoSmithKline Signs Deal with Dynavax Technologies.....II-52
RXi Pharmaceuticals Receives Technology License from UMMS.....II-52
1$100
   Heilongjiang Tianlong Receives Manufacturing Rights for Four Medicines.....II-53
Dara BioSciences Raises Funds for Testing of Drugs.....II-53
Avidas Pharmaceuticals Acquires Rights from Crown Laboratories.....II-53
1$100
   LEO Pharma Sets Up LEO Pharma China.....II-54
Dr Reddy's Established New Subsidiary in the US.....II-54
Lupin to Outlicense Psoriasis Drugs.....II-54
1$100
   Abbott Laboratories (US).....II-55
Amgen Inc. (US).....II-55
1$100
   Almirall SA (Spain).....II-56
Astellas Pharma US, Inc. (US).....II-56
Biogen Idec, Inc. (US).....II-56
1$100
   Eisai Co. Ltd. (Japan).....II-57
Galderma Laboratories (Switzerland).....II-57
1$100
   Isis Pharmaceuticals, Inc. (US).....II-58
Johnson & Johnson Company (US).....II-58
LEO Pharma A/S (Denmark).....II-58
1$100
   Merck & Co., Inc. (US).....II-59
Novartis AG (Switzerland).....II-59
1$100
   Stiefel Laboratories, Inc. (US).....II-60
Teva Pharmaceutical Industries Ltd. (Israel).....II-60
Valeant Pharmaceuticals International (US).....II-60
1$100
   Vertex Pharmaceuticals, Inc. (US).....II-61
Wyeth (US).....II-61
2$125
   Analytics by Geographic Region.....II-63
Table 7: World Recent Past, Current & Future Analysis for Psoriasis Drugs by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-63
1$350
   Table 8: World 10-Year Perspective for Psoriasis Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart).....II-641$350
   Analytics by Drug Administration Route.....II-65
Table 9: World Recent Past, Current & Future Analysis for Psoriasis Drugs by Drug Administration Route - Systemic Drugs and Topical Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-65
1$350
   Table 10: World 10-Year Perspective for Psoriasis Drugs by Drug Administration Route - Percentage Breakdown of Dollar Sales for Systemic Drugs and Topical Drugs Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart).....II-661$350
   A. Market Analysis.....III-1
Current and Future Analysis.....III-1
Major Trends.....III-1
Corticosteroids: Foundation of Mild to Moderate Treatment.....III-1
Dovonex, Taclonex Remain Standard Topical Treatments.....III-1
1$75
   Room for Biologics Penetration As Most Moderate-to-Severe Cases Remain Untreated
  for Psoriasis.....III-2
Enbrel to Lead, Despite Losing Share to Humira.....III-2
1$75
   Humira Cuts into Enbrel’s Share.....III-3
Amgen to Redeem 100% North American Rights for Enbrel.....III-3
J&J's Stelara Unlikely to Take the Market By Storm.....III-3
FDA Delays Enbrel’s Pediatric Psoriasis Indication.....III-3
Genentech Withdraws Raptiva, Triggers Safety Concerns.....III-3
1$75
   Product Launches.....III-42$100
   Strategic Corporate Developments.....III-67$225
   Key Players.....III-135$175
   B. Market Analytics.....III-18
Table 11: US Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-18
1$200
   A. Market Analysis.....III-19
Current and Future Analysis.....III-19
Key Player.....III-19
1$75
   B. Market Analytics.....III-20
Table 12: Japanese Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-20
1$200
   A. Market Analysis.....III-21
Current and Future Analysis.....III-21
Product Launches.....III-21
Strategic Corporate Developments.....III-21
2$100
   Key Players.....III-232$100
   B. Market Analytics.....III-25
Table 13: European Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-25
1$200
   A. Market Analysis.....III-26
Current and Future Analysis.....III-26
Product Launches.....III-26
Strategic Corporate Developments.....III-26
3$125
   B. Market Analytics.....III-29
Table 14: Rest of World Recent Past, Current & Future Analysis for Psoriasis Drugs Market - Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-29
1$200
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com